Toripalimab

Generic Name: Toripalimab

Brand Names: Loqtorzi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1924598-82-2

Unique Ingredient Identifier: 8JXN261VVA

Background: Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).

Indication: ⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: NSCLC

Interventions: Radiation: SBRT+LDRT
Drug: Chemotherapy drug
Drug: Toripalimab

First Posted Date: 2023-04-05

Last Posted Date: 2024-05-17

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 124

Registration Number: NCT05798845

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Immunotherapy After Radiotherapy in Elderly ESCC

Phase 2

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

Interventions: Radiation: Radiotherapy
Drug: Toripalimab

First Posted Date: 2023-03-30

Last Posted Date: 2023-03-30

Lead Sponsor: The Central Hospital of Lishui City

Target Recruit Count: 30

Registration Number: NCT05791136

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Toripalimab

First Posted Date: 2023-03-17

Last Posted Date: 2024-04-01

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 28

Registration Number: NCT05773079

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

Phase 2

Recruiting

Conditions: Non-clear Renal Cell Carcinoma

Interventions: Drug: Toripalimab
Drug: Axitinib

First Posted Date: 2023-03-14

Last Posted Date: 2023-03-14

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 30

Registration Number: NCT05768464

Locations: 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
🇨🇳
Hongqian Guo, Nanning, Jiangsu, China

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Phase 2

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: Fruquintinib
Drug: Toripalimab
Radiation: Short-course radiotherapy
Procedure: TME

First Posted Date: 2023-03-10

Last Posted Date: 2023-03-10

Lead Sponsor: West China Hospital

Target Recruit Count: 44

Registration Number: NCT05763927

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Adenocarcinoma of Esophagogastric Junction
Adenocarcinoma of the Stomach
Mismatch Repair Deficiency

Interventions: Drug: Toripalimab
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2023-02-15

Last Posted Date: 2023-07-25

Lead Sponsor: Yu jiren

Target Recruit Count: 90

Registration Number: NCT05729646

Locations: 🇨🇳
The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
Ningbo Second Hospital, Ningbo, Zhejiang, China
🇨🇳
Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China

and more 5 locations

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Phase 1

Recruiting

Conditions: Melanoma

Interventions: Drug: KD6001
Drug: Toripalimab

First Posted Date: 2023-02-10

Last Posted Date: 2023-04-27

Lead Sponsor: Shanghai Kanda Biotechnology Co., Ltd.

Target Recruit Count: 84

Registration Number: NCT05723432

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Adenocarcinoma of the Stomach
Adenocarcinoma of Esophagogastric Junction
HER2-positive Gastric Cancer

Interventions: Drug: Toripalimab
Drug: Trastuzumab
Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)

First Posted Date: 2023-02-08

Last Posted Date: 2023-03-13

Lead Sponsor: Yu jiren

Target Recruit Count: 30

Registration Number: NCT05715931

Locations: 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
Ningbo First Hospital, Ningbo, Zhejiang, China
🇨🇳
Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China

and more 5 locations

A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Phase 3

Recruiting

Conditions: Toripalimab
Radiation

Interventions: Drug: Toripalimab
Radiation: CRT
Drug: XELIRI
Radiation: SCRT
Drug: FOLFRINOX

First Posted Date: 2022-12-30

Last Posted Date: 2022-12-30

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 174

Registration Number: NCT05669092

Locations: 🇨🇳
Zhengjiang Cancer Hospital, Hangzhou, Zhejiang, China

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Recruiting

Conditions: Lung Cancer

Interventions: Drug: Toripalimab

First Posted Date: 2022-12-15

Last Posted Date: 2022-12-15

Lead Sponsor: Qianfoshan Hospital

Target Recruit Count: 200

Registration Number: NCT05652712

Locations: 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy